|

AG-120 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Institut de Recherches Internationales Servier1

Indications

  • Other IDH1-mutated Positive Hematologic Malignancies1
  • Untreated AML1
  • Relapsed or Refractory Acute Myeloid Leukemia (AML)1
  • Myelodysplastic Syndromes1
  • Cancer1

Birmingham, Alabama1 trial

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

University of Alabama at Birmingham

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.